To the best of our knowledge, there is only case report on T-DXd therapy in HER2 low breast cancer with LM, published in November 2023: a 44-year-old woman with heavily pretreated HR positive HER2 low breast cancer and disease in the bone, liver, pleura, brain, and leptomeningeal disease. The gene discussed is ERBB2; the disease is breast carcinoma.